praziquantel has been researched along with Central Nervous System Cysticercosis in 103 studies
azinox: Russian drug
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study demonstrates the safety and efficacy of albendazole and praziquantel in combination for complete radiologic resolution in children with persistent neurocysticercosis when compared with albendazole monotherapy or placebo." | 9.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 9.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 9.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "A recently described one-day regimen of praziquantel (PZQ) therapy for neurocysticercosis (NCC), three doses of 25 mg/k given at 2 h intervals, was applied in eight patients with viable NCC cysts without any evidence of inflammation." | 9.09 | Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. ( García, HH; Gilman, RH; Martinez, M; Pretell, EJ; Saavedra, H, 2001) |
| "A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis." | 8.84 | Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. ( Adamidi, ES; Falagas, ME; Matthaiou, DK; Panos, G, 2008) |
| "The efficacy of albendazole therapy in patients with parenchymal neurocysticercosis (NCC) is suboptimal." | 7.91 | Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. ( Arroyo, G; Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Rodriguez, S; Saavedra, H; Takayanagui, OM, 2019) |
| " We report a case in which treatment with high-dose praziquantel resulted in prolonged perilesional edema requiring use of corticosteroids and corticosteroid-sparing agents for >1 year, suggesting a role for methotrexate in the management of this condition." | 7.72 | Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent. ( Keiser, PB; Nash, TE, 2003) |
| "Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together." | 6.76 | Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. ( Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Saavedra, H; Takayanagui, OM, 2011) |
| "55%; P = 0." | 6.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| " Conclusion: Praziquantel is effective and safe in the treatment of patients with neurocysticercosis." | 5.72 | Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam. ( Loi, CB; Phuc, TQ; Thang, TD; Thanh, DT; Thieu, NQ; Tho, TH; Tran-Anh, L, 2022) |
| "Praziquantel (PZQ) has been commonly used to treat diverse parasitic infections for over thirty years." | 5.56 | Acute pancytopenia due to praziquantel treatment for cerebral cysticercosis: A rare case report. ( Deng, H; Fu, Y; Lai, J; Li, Q; Zhang, Y, 2020) |
| "Our study demonstrates the safety and efficacy of albendazole and praziquantel in combination for complete radiologic resolution in children with persistent neurocysticercosis when compared with albendazole monotherapy or placebo." | 5.51 | Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial. ( Khandelwal, N; Saini, AG; Singh, K; Singhi, P, 2022) |
| "Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa." | 5.48 | In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach. ( Arrua, EC; Lima, NF; Salomon, CJ; Silva, LD; Vinaud, MC, 2018) |
| "The onset of anthelmintic treatment of neurocysticercosis (NCC) provokes an acute immune response of the host, which in human cases is associated with exacerbation of neurological symptoms." | 5.46 | Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole. ( Arroyo, G; Bustos, JA; Calcina, J; Cangalaya, C; Chacaltana, J; García, HH; Gonzalez, AE; Guerra-Giraldez, C; Mahanty, S; Mamani, J; Nash, TE; Suarez, D; Vargas-Calla, A, 2017) |
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 5.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| "To evaluate the efficacy and safety of a combination of albendazole and praziquantel in children with seizures and single small enhancing computerized tomographic lesions." | 5.14 | Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. ( Kaur, S; Khandelwal, N; Singhi, P; Singhi, S, 2009) |
| "A recently described one-day regimen of praziquantel (PZQ) therapy for neurocysticercosis (NCC), three doses of 25 mg/k given at 2 h intervals, was applied in eight patients with viable NCC cysts without any evidence of inflammation." | 5.09 | Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. ( García, HH; Gilman, RH; Martinez, M; Pretell, EJ; Saavedra, H, 2001) |
| "18 patients with partial epilepsy and neurocysticercosis were treated with albendazol or praziquantel and followed from 3 months to 12 years." | 5.09 | Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis. ( Cardoso, TM; Cendes, F; Guerreiro, CA; Kobayashi, E; Santos, IC, 2000) |
| "Anthelminthic treatment with albendazole provides improved rates of seizure freedom and hastens resolution of the granuloma." | 4.89 | Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. ( Otte, WM; Sander, JW; Singh, G; Singla, M, 2013) |
| "A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis." | 4.84 | Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. ( Adamidi, ES; Falagas, ME; Matthaiou, DK; Panos, G, 2008) |
| "Therapy for neurocysticercosis has advanced during the last 20 years with the advent of albendazole (Zentel) and praziquantel (Cysticide)." | 4.82 | Therapy for neurocysticercosis. ( Takayanagui, OM, 2004) |
| "Four trials met the inclusion criteria, treating intraparenchymatous neurocysticercosis with either albendazole or praziquantel compared to placebo or no treatment." | 4.80 | Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. ( Counsell, C; Garner, P; Gelband, H; Prasad, K; Salinas, R, 1999) |
| "Cyst resolution was unsatisfactory with albendazole monotherapy but was very high when it was followed by a combination of albendazole and praziquantel." | 4.31 | Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. ( Bottieau, E; Carabin, H; Dorny, P; Fleury, A; Gabriël, S; Jackson, E; Magnussen, P; Makasi, C; Mwape, KE; Ngowi, BJ; Prazeres da Costa, C; Prodjinotho, UF; Ruether, C; Schmidt, V; Stelzle, D; Trevisan, C; Van Damme, I; Winkler, AS; Zulu, G, 2023) |
| "The current pharmacological treatment of neurocysticercosis is based on two drugs, praziquantel (PZQ) and albendazole; however, suboptimal efficacy has been documented." | 3.96 | Cysticidal activity of praziquantel-mebendazole combination: In vitro and in vivo studies. ( Fernanda, GM; Francisca, PA; Guadalupe, PH; Helgi, JC; Iliana, GH; Javier, LF; Nelly, C; Susana, RI, 2020) |
| "The efficacy of albendazole therapy in patients with parenchymal neurocysticercosis (NCC) is suboptimal." | 3.91 | Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. ( Arroyo, G; Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Rodriguez, S; Saavedra, H; Takayanagui, OM, 2019) |
| "A patient with paucisymptomatic neurocysticercosis (NCC) diagnosed by Ag-ELISA, and confirmed by MRI images, was treated with praziquantel, albendazole and dexamethasone." | 3.91 | Monitoring treatment of Taenia solium- neurocysticercosis by detection of circulating antigens: a case report. ( Benítez-Ortiz, W; Carpio, A; Rodríguez-Hidalgo, R; Van den Enden, E, 2019) |
| "Albendazole is an anthelmintic drug widely used in the treatment of neurocysticercosis (NCC), an infection of the brain with Taenia solium cysts." | 3.79 | In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium. ( Cass, QB; de Campos Lourenço, T; Dorny, P; García, HH; Guerra-Giraldez, C; Mahanty, S; Marzal, M; Nash, TE; Paredes, A; Rivera, A, 2013) |
| " Lastly, widespread neurocysticercosis may be a concern in mass treatment programs that provide praziquantel (for managing schistosomiasis) or albendazole (for managing intestinal worms or lymphatic filariasis) because these drugs may kill cerebral cysticerci, resulting in severe adverse events." | 3.74 | Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures? ( Eberhard, M; Habumogisha, P; Katabarwa, M; Lakwo, T; Richards, F, 2008) |
| " We report a case in which treatment with high-dose praziquantel resulted in prolonged perilesional edema requiring use of corticosteroids and corticosteroid-sparing agents for >1 year, suggesting a role for methotrexate in the management of this condition." | 3.72 | Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent. ( Keiser, PB; Nash, TE, 2003) |
| "In this study, 65 patients with active neurocysticercosis (NCC) treated with praziquantel or albendazole were retrospectively reviewed to evaluate radiological and clinical outcome." | 3.70 | Outcomes of medical treatment of neurocysticercosis: a study of 65 cases in Cheju Island, Korea. ( Cho, BK; Hong, KS; Kim, SK; Paek, SH; Wang, KC, 1999) |
| "Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together." | 2.76 | Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. ( Bonato, PS; Bustos, JA; Garcia, HH; Gilman, RH; Gonzales, I; Gonzalez, AE; Horton, J; Lanchote, VL; Lescano, AG; Pretell, EJ; Saavedra, H; Takayanagui, OM, 2011) |
| "Neurocysticercosis is a parasitic infection of the central nervous system by the larval stage of the pork tapeworm and is a common cause of seizures and epilepsy in endemic areas." | 2.72 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Monk, EJM; Ranganathan, LN, 2021) |
| "Neurocysticercosis is the most common parasitosis of the central nervous system." | 2.49 | Neurocysticercosis. ( Zymberg, ST, 2013) |
| "Human neurocysticercosis is a severe disease caused by the installation of Taenia solium larvae in the CNS." | 2.48 | Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis. ( Jung-Cook, H, 2012) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| "Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm." | 2.46 | Anthelmintics for people with neurocysticercosis. ( Abba, K; Ramaratnam, S; Ranganathan, LN, 2010) |
| "Neurocysticercosis is a pleomorphic disease due to individual differences in the number and location of the parasites within the nervous system as well as to differences in the severity of the host's immune reaction against the parasite." | 2.43 | [Neurocysticercosis: up-dating in diagnosis and treatment]. ( Del Brutto, OH, 2005) |
| "55%; P = 0." | 2.43 | Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. ( Coffey, CS; Del Brutto, OH; García, HH; Roos, KL, 2006) |
| " Conclusion: Praziquantel is effective and safe in the treatment of patients with neurocysticercosis." | 1.72 | Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam. ( Loi, CB; Phuc, TQ; Thang, TD; Thanh, DT; Thieu, NQ; Tho, TH; Tran-Anh, L, 2022) |
| "Subarachnoid cysticercosis is a type of extra-parenchymal infection in which the prevalence is not known and racemose NC with cerebellar involvement has been rarely reported." | 1.62 | Subarachnoid racemose neurocysticercosis with cerebellar involvement: an old friend in an infrequent location? ( Calderon-Vargas, CM; Montejo-Coy, JA; Parra-Cárdenas, DM; Severiche-Bueno, DF; Vargas-Cuervo, MT, 2021) |
| "Praziquantel (PZQ) has been commonly used to treat diverse parasitic infections for over thirty years." | 1.56 | Acute pancytopenia due to praziquantel treatment for cerebral cysticercosis: A rare case report. ( Deng, H; Fu, Y; Lai, J; Li, Q; Zhang, Y, 2020) |
| "Neurocysticercosis is the most common parasitic infection of the nervous system and currently represents a serious public health issue in many regions of Latin America, Asia, and Africa." | 1.48 | In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach. ( Arrua, EC; Lima, NF; Salomon, CJ; Silva, LD; Vinaud, MC, 2018) |
| "The onset of anthelmintic treatment of neurocysticercosis (NCC) provokes an acute immune response of the host, which in human cases is associated with exacerbation of neurological symptoms." | 1.46 | Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole. ( Arroyo, G; Bustos, JA; Calcina, J; Cangalaya, C; Chacaltana, J; García, HH; Gonzalez, AE; Guerra-Giraldez, C; Mahanty, S; Mamani, J; Nash, TE; Suarez, D; Vargas-Calla, A, 2017) |
| "Albendazole has better therapeutic effects than praziquantel." | 1.43 | [Clinical Analysis of 94 Patients with Neurocysticercosis in Sichuan Province]. ( Hu, TY; Liu, Y; Lv, XJ; Zhong, CJ, 2016) |
| "Taenia solium cysticercosis is a common parasitic infection of humans and pigs." | 1.42 | Successful Antiparasitic Treatment for Cysticercosis is Associated with a Fast and Marked Reduction of Circulating Antigen Levels in a Naturally Infected Pig Model. ( Bustos, JA; Castillo, Y; Dorny, P; Gabriël, S; Garcia, HH; Gilman, RH; Gonzalez, AE; Praet, N; Rodriguez, S; Zimic, M, 2015) |
| "When cerebral cysticercosis were in acute stage (the single and multiple sacculus type, encephalitis type, and macrocyst and sacculus coexistence type), the therapeutic effect was good; while in the mixed type, the therapeutic effect was relatively poor." | 1.40 | [Comparative study on EEG and neuroimaging of patients with cerebral cysticercosis before and after treatment]. ( Fu, TX; Hu, YX; Li, GL; Mao, DH; Tan, WB; Wang, ZL, 2014) |
| "Neurocysticercosis is a widely prevalent disease in the tropics that causes seizures and a variety into of neurological symptoms in most of the world." | 1.39 | Disruption of the blood-brain barrier in pigs naturally infected with Taenia solium, untreated and after anthelmintic treatment. ( Arroyo, G; Balboa, D; Cangalaya, C; García, HH; Gonzales-Gustavson, E; González, AE; Guerra-Giraldez, C; Mahanty, S; Marzal, M; Nash, TE; Orrego, MÁ; Paredes, A, 2013) |
| "Neurocysticercosis is an unusual cause of seizure in the New Zealand setting." | 1.38 | Neurocysticercosis: an unusual cause of seizure in the New Zealand setting. ( Heron, P; Pybus, M, 2012) |
| "Neurocysticercosis was easy to misdiagnose." | 1.35 | Clinical analysis of 52 cases of neurocysticercosis. ( Chaoshuang, L; Xiaohong, W; Zhanlian, H; Zhiliang, G; Zhixin, Z, 2008) |
| "Neurocysticercosis is a pathology that we are finding nowadays over the immigrant population." | 1.32 | [Neurocysticercosis: report of three cases and recommendations of treatment]. ( Alvarez Rodríguez, E; Cabello, J; Espinós Pérez, D; Gutiérrez Larráinzar, A; Torres-Gárate, R, 2004) |
| "Cysticercosis is an helminthic disease which is usually observed in endemic areas or in immigrants coming from these areas." | 1.32 | [Neurocysticercosis complicating the treatment of cutaneous cysticercosis in a traveller]. ( Bricaire, E; Caumes, E; Chemali, N; Danis, M; Epelboin, L; Klement, E, 2004) |
| "Cysticercosis is a disease caused by the hydatid of the porcine tapeworm (cysticercus)." | 1.32 | [Cysticercosis as a rare cause of a tumor of the tongue]. ( Gocht, A; Metternich, FU; Roth, B, 2003) |
| "A 29-year-old man presented focal seizure on the left side." | 1.31 | [A case of neurocysticercosis presenting as focal seizure]. ( Higuchi, H; Kobayashi, N; Okada, T; Sugiyama, M; Teramoto, A; Yabe, Y, 2000) |
| "Treatment with praziquantel associated with cimetidine to increase the drug bioavailability and prednisone to reduce the inflammatory reaction gives good results." | 1.30 | Parenchymatous cerebral neurocysticercosis in a quadriplegic patient. ( Al-Khodairy, AT; Annoni, JM; Uebelhart, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (8.74) | 18.2507 |
| 2000's | 34 (33.01) | 29.6817 |
| 2010's | 46 (44.66) | 24.3611 |
| 2020's | 14 (13.59) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, K | 1 |
| Saini, AG | 1 |
| Khandelwal, N | 2 |
| Singhi, P | 2 |
| Cunningham, FG | 1 |
| Twickler, DM | 1 |
| Takayanagui, OM | 6 |
| Haes, TM | 1 |
| Thang, TD | 1 |
| Phuc, TQ | 1 |
| Thanh, DT | 1 |
| Thieu, NQ | 1 |
| Tho, TH | 1 |
| Loi, CB | 1 |
| Tran-Anh, L | 1 |
| Stelzle, D | 1 |
| Makasi, C | 1 |
| Schmidt, V | 1 |
| Trevisan, C | 1 |
| Van Damme, I | 1 |
| Ruether, C | 1 |
| Dorny, P | 3 |
| Magnussen, P | 1 |
| Zulu, G | 1 |
| Mwape, KE | 1 |
| Bottieau, E | 1 |
| Prazeres da Costa, C | 1 |
| Prodjinotho, UF | 1 |
| Carabin, H | 1 |
| Jackson, E | 1 |
| Fleury, A | 3 |
| Gabriël, S | 2 |
| Ngowi, BJ | 1 |
| Winkler, AS | 1 |
| Nash, TE | 9 |
| O'Connell, EM | 1 |
| Hammoud, DA | 1 |
| Wetzler, L | 1 |
| Ware, JM | 2 |
| Mahanty, S | 8 |
| Francisca, PA | 1 |
| Javier, LF | 1 |
| Guadalupe, PH | 1 |
| Fernanda, GM | 1 |
| Nelly, C | 1 |
| Helgi, JC | 1 |
| Iliana, GH | 1 |
| Susana, RI | 1 |
| Del Brutto, OH | 8 |
| Pérez-Jacoiste Asín, MA | 1 |
| Calleja-Castaño, P | 1 |
| Hilario, A | 1 |
| Zhang, Y | 1 |
| Fu, Y | 1 |
| Deng, H | 1 |
| Li, Q | 1 |
| Lai, J | 1 |
| Ramiandrasoa, NS | 1 |
| Ravoniarimbinina, P | 1 |
| Solofoniaina, AR | 1 |
| Andrianjafy Rakotomanga, IP | 1 |
| Andrianarisoa, SH | 1 |
| Molia, S | 1 |
| Labouche, AM | 1 |
| Fahrion, AS | 1 |
| Donadeu, M | 1 |
| Abela-Ridder, B | 1 |
| Rajaonatahina, D | 1 |
| Landzberg, DR | 1 |
| Dhir, A | 1 |
| Jillella, DV | 1 |
| Monk, EJM | 1 |
| Abba, K | 3 |
| Ranganathan, LN | 3 |
| Parra-Cárdenas, DM | 1 |
| Vargas-Cuervo, MT | 1 |
| Montejo-Coy, JA | 1 |
| Calderon-Vargas, CM | 1 |
| Severiche-Bueno, DF | 1 |
| Cangalaya, C | 4 |
| Bustos, JA | 7 |
| Calcina, J | 2 |
| Vargas-Calla, A | 1 |
| Mamani, J | 1 |
| Suarez, D | 1 |
| Arroyo, G | 4 |
| Gonzalez, AE | 8 |
| Chacaltana, J | 1 |
| Guerra-Giraldez, C | 5 |
| García, HH | 16 |
| Orrego, MA | 2 |
| Adrianzen, MP | 1 |
| Liu, P | 1 |
| Weng, X | 1 |
| Zhou, J | 1 |
| Xu, X | 1 |
| He, F | 1 |
| Du, Y | 1 |
| Wu, H | 1 |
| Gong, Y | 1 |
| Peng, G | 1 |
| Silva, LD | 1 |
| Lima, NF | 1 |
| Arrua, EC | 1 |
| Salomon, CJ | 1 |
| Vinaud, MC | 2 |
| Liu, Y | 1 |
| Hu, TY | 1 |
| Zhong, CJ | 1 |
| Lv, XJ | 1 |
| Toledo, A | 1 |
| Osorio, R | 1 |
| Matus, C | 1 |
| Martinez Lopez, Y | 1 |
| Ramirez Cruz, N | 1 |
| Sciutto, E | 2 |
| Fragoso, G | 1 |
| Arauz, A | 1 |
| Carrillo-Mezo, R | 2 |
| Coyle, CM | 1 |
| Lescano, AG | 4 |
| Gonzales, I | 5 |
| Saavedra, H | 6 |
| Rodriguez, S | 2 |
| Pretell, EJ | 7 |
| Bonato, PS | 3 |
| Lanchote, VL | 3 |
| Horton, J | 3 |
| Gilman, RH | 6 |
| Rodríguez-Hidalgo, R | 1 |
| Carpio, A | 3 |
| Van den Enden, E | 1 |
| Benítez-Ortiz, W | 1 |
| Marzal, M | 3 |
| Balboa, D | 1 |
| Paredes, A | 2 |
| Gonzales-Gustavson, E | 1 |
| Romo, ML | 2 |
| Kelvin, EA | 1 |
| de Almeida Leandro, L | 1 |
| Fraga, CM | 1 |
| de Souza Lino, R | 1 |
| Karegowda, LH | 1 |
| Shenoy, PM | 1 |
| Prakashini, K | 1 |
| Karur, G | 1 |
| Singh, G | 3 |
| White, AC | 1 |
| Zimic, M | 3 |
| Escalante, D | 1 |
| Gavidia, M | 2 |
| Rodriguez, L | 2 |
| Najar, E | 2 |
| Umeres, H | 2 |
| Wang, ZL | 1 |
| Fu, TX | 1 |
| Hu, YX | 1 |
| Li, GL | 1 |
| Mao, DH | 1 |
| Tan, WB | 1 |
| Valadas, E | 1 |
| Badura, R | 1 |
| Marques, T | 1 |
| Neno, M | 1 |
| Boura, M | 1 |
| Sutre, AF | 1 |
| Beato, S | 1 |
| Grácio, MA | 1 |
| Neves, JC | 1 |
| Ahmed, S | 1 |
| Paul, SP | 1 |
| Mahamat, A | 1 |
| Abboud, P | 1 |
| Demar, M | 1 |
| JeanBourquin, D | 1 |
| Djossou, F | 1 |
| Wang, W | 1 |
| Castillo, Y | 1 |
| Praet, N | 1 |
| Li, Y | 1 |
| Sun, L | 1 |
| Chen, C | 1 |
| Yang, CM | 1 |
| Ghasemi, R | 1 |
| Rowe, A | 1 |
| Shah, R | 1 |
| Venkatesan, P | 1 |
| England, TJ | 1 |
| Chaoshuang, L | 1 |
| Zhixin, Z | 1 |
| Xiaohong, W | 1 |
| Zhanlian, H | 1 |
| Zhiliang, G | 1 |
| Kaur, S | 1 |
| Singhi, S | 1 |
| Proaño, JV | 2 |
| Torres-Corzo, J | 1 |
| Rodríguez-Della Vecchia, R | 1 |
| Guizar-Sahagun, G | 1 |
| Rangel-Castilla, L | 1 |
| Maïga, Y | 1 |
| Diallo, M | 1 |
| Bouteille, B | 1 |
| Konate, A | 1 |
| Diarra, M | 1 |
| Maïga, M | 1 |
| Marjolet, M | 1 |
| Ramaratnam, S | 2 |
| Cárdenas, G | 1 |
| Jung, H | 2 |
| Hernandez, JL | 1 |
| Sotelo, J | 2 |
| Diaz-Olavarrieta, C | 1 |
| Hewagama, SS | 1 |
| Darby, JD | 1 |
| Sheorey, H | 1 |
| Daffy, JR | 1 |
| Pybus, M | 1 |
| Heron, P | 1 |
| Odashima, NS | 1 |
| Lima, JE | 1 |
| Jung-Cook, H | 1 |
| Wandra, T | 1 |
| Sudewi, AA | 1 |
| Swastika, IK | 1 |
| Sutisna, P | 1 |
| Dharmawan, NS | 1 |
| Yulfi, H | 1 |
| Darlan, DM | 1 |
| Kapti, IN | 1 |
| Samaan, G | 1 |
| Sato, MO | 1 |
| Okamoto, M | 1 |
| Sako, Y | 1 |
| Ito, A | 1 |
| Zymberg, ST | 1 |
| Madrid, EM | 1 |
| de Campos Lourenço, T | 1 |
| Rivera, A | 1 |
| Cass, QB | 1 |
| Otte, WM | 1 |
| Singla, M | 1 |
| Sander, JW | 2 |
| Al Shahrani, D | 1 |
| Frayha, HH | 1 |
| Dabbagh, O | 1 |
| Al Shail, E | 1 |
| Keiser, PB | 1 |
| Narula, G | 1 |
| Bawa, KS | 1 |
| Roth, B | 1 |
| Gocht, A | 1 |
| Metternich, FU | 1 |
| Guo, DM | 1 |
| Xie, SP | 1 |
| Jia, JP | 1 |
| Kim, JS | 1 |
| Jeong, SM | 1 |
| Moon, SY | 1 |
| Park, SH | 1 |
| Alvarez Rodríguez, E | 1 |
| Torres-Gárate, R | 1 |
| Gutiérrez Larráinzar, A | 1 |
| Cabello, J | 1 |
| Espinós Pérez, D | 1 |
| Sheehan, JP | 1 |
| Sheehan, J | 1 |
| Lopes, MB | 1 |
| Jane, JA | 1 |
| DeGiorgio, CM | 1 |
| Houston, I | 1 |
| Oviedo, S | 1 |
| Sorvillo, F | 1 |
| Pawlowski, ZS | 1 |
| Roos, KL | 1 |
| Coffey, CS | 1 |
| Nogales-Gaete, J | 1 |
| Arriagada, C | 1 |
| Salinas, R | 4 |
| Epelboin, L | 1 |
| Klement, E | 1 |
| Chemali, N | 1 |
| Danis, M | 1 |
| Bricaire, E | 1 |
| Caumes, E | 1 |
| Prasad, K | 3 |
| Matthaiou, DK | 1 |
| Panos, G | 1 |
| Adamidi, ES | 1 |
| Falagas, ME | 1 |
| Katabarwa, M | 1 |
| Lakwo, T | 1 |
| Habumogisha, P | 1 |
| Richards, F | 1 |
| Eberhard, M | 1 |
| Yee, T | 1 |
| Barakos, JA | 1 |
| Knight, RT | 1 |
| Al-Khodairy, AT | 1 |
| Annoni, JM | 1 |
| Uebelhart, D | 1 |
| Campos, X | 1 |
| Sánchez, J | 1 |
| Mosquera, A | 1 |
| Isozumi, K | 1 |
| Izumi, Y | 1 |
| Monteiro, L | 1 |
| Lopes, J | 1 |
| Martins da Silva, A | 1 |
| Counsell, C | 1 |
| Gelband, H | 1 |
| Garner, P | 1 |
| Kim, SK | 1 |
| Wang, KC | 1 |
| Paek, SH | 1 |
| Hong, KS | 1 |
| Cho, BK | 1 |
| Morales, NM | 1 |
| Agapejev, S | 1 |
| Morales, RR | 1 |
| Padula, NA | 1 |
| Lima, MM | 1 |
| Djientcheu, VD | 1 |
| Zona, G | 1 |
| Rilliet, B | 1 |
| Gogna, A | 1 |
| Sugiyama, M | 1 |
| Okada, T | 1 |
| Higuchi, H | 1 |
| Yabe, Y | 1 |
| Kobayashi, N | 1 |
| Teramoto, A | 1 |
| Santos, IC | 1 |
| Kobayashi, E | 1 |
| Cardoso, TM | 1 |
| Guerreiro, CA | 1 |
| Cendes, F | 1 |
| Custodio, N | 1 |
| Padilla, C | 1 |
| Alvarado, M | 1 |
| Martinez, M | 2 |
| Belo, M | 1 |
| Grunitzky, EK | 1 |
| Balogou, A | 1 |
| Kowu, L | 1 |
| Madrazo, I | 1 |
| Avelar, F | 1 |
| López-Félix, B | 1 |
| Díaz, G | 1 |
| Grijalva, I | 1 |
| López-Gómez, M | 1 |
| Castro, N | 1 |
| Corona, T | 1 |
| Lev, N | 1 |
| Michowiz, S | 1 |
| Inbar, E | 1 |
| Coire, CI | 1 |
| Pitlik, S | 1 |
| Melamed, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characteristics of Patients With Symptomatic Active Neurocysticercosis and Effect of Treatment on Symptoms, Lesions and Quality of Life in Resource-poor Rural Areas of Eastern Africa - TOPANA, a Multi-centre Prospective Cohort Study.[NCT03834337] | 63 participants (Actual) | Observational | 2019-04-01 | Completed | |||
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole[NCT00441285] | Phase 2/Phase 3 | 156 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients whose 6 month MR does not show viable parasites anymore (NCT00441285)
Timeframe: Day 180
| Intervention | participants (Number) |
|---|---|
| Phase III Trial - ABZ+PZQ | 25 |
| Phase III Trial - Increased ABZ | 19 |
| Phase III Trial - Standard ABZ | 15 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Albendazole + Praziquantel | 4925.3 |
| Albendazole + Placebo | 2969.6 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1
| Intervention | ng*h/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1412.2 |
| Albendazole + Placebo | 1111 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Carbamazepine | 240.2 |
| Phenytoin | 550.1 |
Highest serum level of Albendazole measured from all level assessments in the curve. (NCT00441285)
Timeframe: Treatment day 1 and Treatment days 10-11
| Intervention | ng/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1293.9 |
| Albendazole + Placebo | 2232.8 |
- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy. (NCT00441285)
Timeframe: 90 days post tx
| Intervention | Events (Number) |
|---|---|
| Albendazole + Praziquantel | 0 |
| Albendazole + Placebo | 0 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1
| Intervention | ng*h / mL (Mean) | |
|---|---|---|
| Carbamazepine (n=8) | Phenytoin (n=8) | |
| Albendazole + Praziquantel | 548.3 | 923.7 |
28 reviews available for praziquantel and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Update on the diagnosis and management of neurocysticercosis.
Topics: Albendazole; Epilepsy; Humans; Magnetic Resonance Imaging; Neurocysticercosis; Praziquantel | 2022 |
Current approaches to cysticidal drug therapy for neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain; Cysticercus; Drug Therapy, Combination; Humans; Neurocys | 2020 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Bias; Brain Diseases; Child; Humans; Neurocysticercosis; Pl | 2021 |
Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution.
Topics: Albendazole; Anticestodal Agents; Antiparasitic Agents; Brain; Cysts; Epilepsy; Female; Humans; Infl | 2017 |
Neurocysticercosis.
Topics: Albendazole; Anthelmintics; Humans; Neurocysticercosis; Praziquantel | 2013 |
Neurocysticercosis.
Topics: Animals; Antiparasitic Agents; Antiplatyhelmintic Agents; Humans; Neurocysticercosis; Neurosurgical | 2014 |
Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?
Topics: Adrenal Cortex Hormones; Albendazole; Animals; Anthelmintics; Anticonvulsants; Drug Interactions; Hi | 2014 |
Anthelmintics for people with neurocysticercosis.
Topics: Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neurocysticercosis; Praziqua | 2010 |
Anthelmintics for people with neurocysticercosis.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Anticestodal Agents; Brain Diseases; Child; Humans; Neu | 2010 |
Medical management of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Brain Diseases; Humans; Life Cycle Stages; Magnetic Resonance I | 2011 |
Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Humans; Neurocysticercosis; Praziquantel; Treatment Outcome | 2012 |
Taeniasis/cysticercosis in Bali, Indonesia.
Topics: Animals; Anthelmintics; Cysticercosis; DNA, Helminth; DNA, Mitochondrial; Health Surveys; Humans; In | 2011 |
Neurocysticercosis.
Topics: Animals; Antiplatyhelmintic Agents; Cerebral Ventricles; Endoscopy; Humans; Neurocysticercosis; Neur | 2013 |
Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.
Topics: Adolescent; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Calcinosis; Child; Child, Preschoo | 2013 |
Neurocysticercosis--New Millennium, ancient disease and unending debate.
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Humans; Neurocysticercosis; Praziquantel; Seiz | 2003 |
Therapy for neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Clinical Trials as Topic; Humans; Neurocysticercosis; Practice | 2004 |
Intramedullary spinal cysticercosis. Case report and review of the literature.
Topics: Adolescent; Anthelmintics; Cervical Vertebrae; Female; Hand; Humans; Laminectomy; Magnetic Resonance | 2002 |
Deaths associated with cysticercosis. Report of three cases and review of the literature.
Topics: Adult; Aged; Anthelmintics; Cerebrospinal Fluid Shunts; Fatal Outcome; Headache; Humans; Hydrocephal | 2002 |
[Neurocysticercosis: up-dating in diagnosis and treatment].
Topics: Albendazole; Animals; Anthelmintics; Antibodies; Humans; Neurocysticercosis; Praziquantel; Taenia so | 2005 |
Role of chemotherapy of taeniasis in prevention of neurocysticercosis.
Topics: Animals; Anticestodal Agents; Cysticercus; Humans; Neurocysticercosis; Niclosamide; Praziquantel; Ta | 2006 |
Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel.
Topics: Albendazole; Anthelmintics; Humans; Neurocysticercosis; Praziquantel; Radiography; Secondary Prevent | 2006 |
[Treatment of neurocysticercosis: a review].
Topics: Albendazole; Animals; Anthelmintics; Bacterial Vaccines; Evidence-Based Medicine; Humans; Neurocysti | 2006 |
WITHDRAWN: Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2007 |
Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
Topics: Albendazole; Clinical Trials as Topic; Humans; Neurocysticercosis; Praziquantel; Randomized Controll | 2008 |
[Neurocysticercosis].
Topics: Albendazole; Animals; Anticestodal Agents; Diagnosis, Differential; Host-Parasite Interactions; Huma | 1999 |
Treating neurocysticercosis medically: a systematic review of randomized, controlled trials.
Topics: Albendazole; Anthelmintics; Anticestodal Agents; Humans; Neurocysticercosis; Praziquantel; Randomize | 1999 |
Drugs for treating neurocysticercosis (tapeworm infection of the brain).
Topics: Albendazole; Anticestodal Agents; Brain Diseases; Humans; Neurocysticercosis; Praziquantel; Trichlor | 2000 |
Neurocysticercosis.
Topics: Anthelmintics; Brain; Brain Diseases; Female; Humans; Middle Aged; Neurocysticercosis; Praziquantel; | 2002 |
11 trials available for praziquantel and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Efficacy of Combination Therapy of Albendazole and Praziquantel vs Albendazole Monotherapy in Children With Persistent Neurocysticercosis: A Randomized Controlled Trial.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Child, Preschool; Drug Therapy, Combination; Humans; | 2022 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anticestodal Agents; Brain Diseases; Female; Humans; Male; | 2016 |
Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial.
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Child; Child, Preschool; Double-Blind Method; Drug | 2009 |
Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Drug Therapy, Combination; Female; Humans; M | 2011 |
Single-day praziquantel versus 1-week albendazole for neurocysticercosis.
Topics: Adult; Aged; Albendazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neurocyst | 1999 |
Cysticidal therapy: impact on seizure control in epilepsy associated with neurocysticercosis.
Topics: Adult; Aged; Albendazole; Anticestodal Agents; Epilepsy; Follow-Up Studies; Humans; Magnetic Resonan | 2000 |
Short regimen of praziquantel in the treatment of single brain enhancing lesions.
Topics: Adolescent; Adult; Animals; Anthelmintics; Female; Humans; Male; Middle Aged; Neurocysticercosis; Pr | 2000 |
Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions.
Topics: Adult; Animals; Anthelmintics; Brain Diseases; Cysticercus; Female; Humans; Male; Middle Aged; Neuro | 2001 |
Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anticestodal Agents; Brain Diseases; Dexame | 2001 |
Optimization of the single-day praziquantel therapy for neurocysticercosis.
Topics: Adolescent; Adult; Cimetidine; Dietary Carbohydrates; Dose-Response Relationship, Drug; Drug Adminis | 2001 |
64 other studies available for praziquantel and Central Nervous System Cysticercosis
| Article | Year |
|---|---|
Neurocysticercosis Complicating Pregnancy.
Topics: Albendazole; Anthelmintics; Female; Headache; Humans; Hydrocephalus; Infant, Newborn; Neurocysticerc | 2022 |
Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam.
Topics: Alanine Transaminase; Albendazole; Anthelmintics; Anticonvulsants; Antiparasitic Agents; Aspartate A | 2022 |
Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study.
Topics: Albendazole; Anthelmintics; Antiparasitic Agents; Cysts; Humans; Neurocysticercosis; Praziquantel; P | 2023 |
Natural History of Treated Subarachnoid Neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Antigens, Helminth | 2020 |
Cysticidal activity of praziquantel-mebendazole combination: In vitro and in vivo studies.
Topics: Albendazole; Animals; Anthelmintics; Blood-Brain Barrier; Cysticercosis; Drug Combinations; Mebendaz | 2020 |
Lumbosacral Radiculopathy as the Clinical Presentation of Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Antibodies, Helminth; Female; Humans; I | 2020 |
Acute pancytopenia due to praziquantel treatment for cerebral cysticercosis: A rare case report.
Topics: Aged; Cysticercosis; Humans; Male; Middle Aged; Neurocysticercosis; Pancytopenia; Praziquantel | 2020 |
Impact of a 3-year mass drug administration pilot project for taeniasis control in Madagascar.
Topics: Adult; Animals; Child; Cross-Sectional Studies; Feces; Humans; Madagascar; Mass Drug Administration; | 2020 |
Radiographic Improvement of Larval Cysts in Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anticonvulsants; Brain; Humans; Magnetic Resonance Imaging; Male; | 2021 |
Subarachnoid racemose neurocysticercosis with cerebellar involvement: an old friend in an infrequent location?
Topics: Cysticercosis; Friends; Humans; Neurocysticercosis; Praziquantel | 2021 |
Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole.
Topics: Albendazole; Animals; Anthelmintics; Brain; Cysts; Disease Models, Animal; Drug Therapy, Combination | 2017 |
TNF-α blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.
Topics: Animals; Anticestodal Agents; Antiparasitic Agents; Blood-Brain Barrier; Brain; Cytokines; Dexametha | 2017 |
Next generation sequencing based pathogen analysis in a patient with neurocysticercosis: a case report.
Topics: Adult; Animals; Anthelmintics; Brain; DNA, Helminth; Female; Headache; High-Throughput Nucleotide Se | 2018 |
In vivo treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach.
Topics: Animals; Anthelmintics; Cysticercus; Disease Models, Animal; Drug Stability; Metabolome; Metabolomic | 2018 |
[Clinical Analysis of 94 Patients with Neurocysticercosis in Sichuan Province].
Topics: Adult; Albendazole; Antibodies; China; Diagnostic Errors; Enzyme-Linked Immunosorbent Assay; Female; | 2016 |
Human Extraparenchymal Neurocysticercosis: The Control of Inflammation Favors the Host…but Also the Parasite.
Topics: Adrenal Cortex Hormones; Animals; Anthelmintics; Biomarkers; Brain; Drug Therapy, Combination; Foodb | 2018 |
Etanercept to Control Inflammation in the Treatment of Complicated Neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Female; Huma | 2019 |
Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Chromatography, High Pressure Liquid; Female; H | 2019 |
Monitoring treatment of Taenia solium- neurocysticercosis by detection of circulating antigens: a case report.
Topics: Adult; Animals; Anthelmintics; Antibodies, Helminth; Enzyme-Linked Immunosorbent Assay; Humans; Male | 2019 |
Disruption of the blood-brain barrier in pigs naturally infected with Taenia solium, untreated and after anthelmintic treatment.
Topics: Animals; Anthelmintics; Blood-Brain Barrier; Brain; Coloring Agents; Evans Blue; Extravasation of Di | 2013 |
Partial reverse of the TCA cycle is enhanced in Taenia crassiceps experimental neurocysticercosis after in vivo treatment with anthelminthic drugs.
Topics: Albendazole; Animals; Anthelmintics; Brain; Chromatography, High Pressure Liquid; Citric Acid Cycle; | 2014 |
A rare case of racemose neurocysticercosis of the posterior fossa.
Topics: Adult; Anthelmintics; Brain; Cerebellopontine Angle; Craniotomy; Fourth Ventricle; Humans; Hydroceph | 2014 |
Determining better treatments for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2014 |
Treatment of neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2014 |
[Comparative study on EEG and neuroimaging of patients with cerebral cysticercosis before and after treatment].
Topics: Adolescent; Adult; Aged; Albendazole; Antiparasitic Agents; Electroencephalography; Female; Humans; | 2014 |
A case of imported neurocysticercosis in Portugal.
Topics: Anthelmintics; Cerebrospinal Fluid; Female; Guinea-Bissau; Head; Humans; Magnetic Resonance Imaging; | 2015 |
Intramedullary spinal neurocysticercosis treated successfully with medical therapy.
Topics: Anthelmintics; Humans; Male; Neurocysticercosis; Praziquantel; Spinal Diseases; Young Adult | 2014 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Combined antiparasitic treatment for neurocysticercosis - Authors' reply.
Topics: Albendazole; Anthelmintics; Female; Humans; Male; Neurocysticercosis; Praziquantel | 2015 |
Successful Antiparasitic Treatment for Cysticercosis is Associated with a Fast and Marked Reduction of Circulating Antigen Levels in a Naturally Infected Pig Model.
Topics: Albendazole; Animals; Anticestodal Agents; Antigens, Helminth; Benzimidazoles; Cysticercosis; Diseas | 2015 |
Inflammation Caused by Praziquantel Treatment Depends on the Location of the Taenia solium Cysticercus in Porcine Neurocysticercosis.
Topics: Animals; Anthelmintics; Brain; Histocytochemistry; Inflammation; Meninges; Neurocysticercosis; Prazi | 2015 |
[Clinical application of diagnostic therapy of praziquantel for suspected cere- bral cysticercosis].
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Child; Child, Preschool; Cysticercus; Drug Administ | 2015 |
Neurocysticercosis presenting as a 'Stroke Mimic'.
Topics: Albendazole; Anticestodal Agents; Brain; Diagnosis, Differential; Glucocorticoids; Humans; Magnetic | 2016 |
Clinical analysis of 52 cases of neurocysticercosis.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Brain; Brain Diseases; Child; China; Female; Humans; | 2008 |
Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Cerebral Ventricles; Child; Female; Follow-Up S | 2009 |
[About an autochtonous case of neurocysticercosis in Mali].
Topics: Albendazole; Anthelmintics; Brain Edema; Calcinosis; Consciousness Disorders; Diet; Drug Therapy, Co | 2009 |
Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series.
Topics: Adult; Aged; Albendazole; Anthelmintics; Brain; Female; Humans; Magnetic Resonance Imaging; Male; Me | 2010 |
Neurocysticercosis: changes after 25 years of medical therapy.
Topics: Anthelmintics; Humans; Neurocysticercosis; Praziquantel | 2010 |
Seizures related to praziquantel therapy in neurocysticercosis.
Topics: Anthelmintics; Humans; Male; Neurocysticercosis; Praziquantel; Seizures; Young Adult | 2010 |
Neurocysticercosis: an unusual cause of seizure in the New Zealand setting.
Topics: Anthelmintics; Child; Humans; Male; Neurocysticercosis; New Zealand; Praziquantel; Radiography; Seiz | 2012 |
Neurocysticercosis in Australia: still free of autochthonous cases?
Topics: Anthelmintics; Female; Frontal Lobe; Humans; Male; Neurocysticercosis; Praziquantel; Refugees; Seizu | 2012 |
Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps.
Topics: Alkaline Phosphatase; Animals; Anticestodal Agents; Artemisinins; Artesunate; Benzamides; Epilepsy; | 2013 |
In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium.
Topics: Albendazole; Alkaline Phosphatase; Animals; Anticestodal Agents; Neurocysticercosis; Praziquantel; S | 2013 |
First case of neurocysticercosis in Saudi Arabia.
Topics: Brain Diseases; Female; Humans; Infant; Neurocysticercosis; Praziquantel; Saudi Arabia | 2003 |
Prolonged perilesional edema after treatment of parenchymal neurocysticercosis: methotrexate as a corticosteroid-sparing agent.
Topics: Adrenal Cortex Hormones; Albendazole; Animals; Anthelmintics; Edema; Humans; Male; Methotrexate; Mid | 2003 |
[Cysticercosis as a rare cause of a tumor of the tongue].
Topics: Adult; Anthelmintics; Cerebral Cortex; Combined Modality Therapy; Cysticercosis; Diagnosis, Differen | 2003 |
[Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis].
Topics: Adult; Albendazole; Anthelmintics; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neu | 2003 |
Anticysticercal treatment and seizures in neurocysticercosis.
Topics: Albendazole; Animals; Anthelmintics; Clinical Trials as Topic; Humans; Neurocysticercosis; Praziquan | 2004 |
Third cranial nerve palsy from midbrain neurocysticercosis: repeated exacerbation on tapering corticosteroids.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Blepharoptosis; Cerebrospinal Fluid; Cysticerc | 2004 |
[Neurocysticercosis: report of three cases and recommendations of treatment].
Topics: Adult; Anthelmintics; Female; Humans; Magnetic Resonance Imaging; Male; Neurocysticercosis; Practice | 2004 |
[Neurocysticercosis complicating the treatment of cutaneous cysticercosis in a traveller].
Topics: Adult; Albendazole; Anthelmintics; Brain Edema; Combined Modality Therapy; Confusion; Cysticercosis; | 2004 |
Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
Topics: Albendazole; Animals; Anthelmintics; Epilepsy; Humans; Neurocysticercosis; Onchocerca; Onchocerciasi | 2008 |
High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up.
Topics: Adult; Antiplatyhelmintic Agents; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Neuro | 1999 |
Parenchymatous cerebral neurocysticercosis in a quadriplegic patient.
Topics: Animals; Anticestodal Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neck; Nervous S | 1999 |
Relationship between cysticercosis and epilepsy.
Topics: Albendazole; Animals; Anthelmintics; Anticestodal Agents; Drug Administration Schedule; Epilepsy; Hu | 1999 |
Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Perú.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albendazole; Animals; Anthelmintics; Brain Diseases; Car | 1999 |
Outcomes of medical treatment of neurocysticercosis: a study of 65 cases in Cheju Island, Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Female; Follow-Up Studies; H | 1999 |
Clinical aspects of neurocysticercosis in children.
Topics: Albendazole; Anthelmintics; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Eosinophils; Epil | 2000 |
Neurocysticercosis: migration and proliferation of cysticercus in a CSF valve.
Topics: Albendazole; Anthelmintics; Humans; Hydrocephalus; Male; Middle Aged; Neurocysticercosis; Praziquant | 2000 |
Praziquantel therapy in neurocysticercosis.
Topics: Albendazole; Anthelmintics; Brain; Humans; Neurocysticercosis; Praziquantel; Sensitivity and Specifi | 1996 |
[A case of neurocysticercosis presenting as focal seizure].
Topics: Adult; Albendazole; Anthelmintics; Brain Diseases; Combined Modality Therapy; Humans; Male; Neurocys | 2000 |
[Cerebral cysticercosis and headache in a young Togolese woman].
Topics: Adult; Anthelmintics; Brain Diseases; Female; France; Headache; Humans; Neurocysticercosis; Praziqua | 2001 |